Browsing by Author "Yalcin, Tugba Yanik"

Now showing 1 - 8 of 8

Booster Shots and Additional Doses for COVID-19 in Solid Organ Recipients
(2022) Erol, Cigdem; Sari, Nuran; Yalcin, Tugba Yanik; Akdur, Aydincan; Arslan, Hande; Haberal, Mehmet; 0000-0002-2535-2534; 0000-0002-3462-7632; AAJ-1219-2021; AAJ-8097-2021
Comparision of Influenza and Covid-19 Infections in Solid Organ Transplant Recipients
(2022) Yalcin, Tugba Yanik; Yuce, Gulbahar Darilmaz; Soy, Ebru H. Ayvazoglu; Azap, Ozlem Kurt; Arslan, Hande; Haberal, Mehmet; 0000-0002-3462-7632; AAJ-8097-2021; JBS-4193-2023
COVID-19 Clinical Outcomes, Coinfection and Secondary Infections in Solid Organ Transplant Recipients
(2022) Yalcin, Tugba Yanik; Erol, Cigdem; Karakaya, Emre; Arslan, Hande; Haberal, Mehmet; 0000-0002-2535-2534; 0000-0002-4879-7974; 0000-0002-3462-7632; AAJ-1219-2021; AAD-5466-2021; AAJ-8097-2021
Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients
(2021) Erol, Cigdem; Yalcin, Tugba Yanik; Sari, Nuran; Bayraktar, Nilufer; Soy, Ebru Ayvazoglu; Colak, Meric Yavuz; Azap, Ozlem; Arslan, Hande; Haberal, Mehmet; 0000-0002-3462-7632; 0000-0002-2535-2534; 0000-0002-0993-9917; 0000-0002-5708-7915; 0000-0001-5996-8639; 0000-0002-3165-4520; 34951350; AAJ-1219-2021; AAC-5566-2019; AAJ-8097-2021; ABG-7034-2021; AAA-4708-2022
Objectives: Vaccination against SARS-CoV-2 may reduce COVID-19 mortality and complications in solidorgan transplant recipients, and we evaluated the associated antibody responses and adverse effects in this high-risk population. Materials and Methods: This prospective observational study (April-June 2021) included 10 liver and 38 kidney transplant recipients who received 2 vaccine doses (Sinovac, n = 31; or BioNTech, n = 17) and 56 healthy adults (Sinovac), all of whom provided 3 blood samples (prevaccination, 4 weeks after first dose, and 4-6 weeks after second dose) for quantitative tests (Abbott Quant assay for immunoglobulin G antibodies against SARS-CoV-2 spike protein). Type I error was alpha = .05 in all statistical analyses (SPSS, version 25). Results: We analyzed demographic data, antibody responses, and adverse events after 2 doses of SARS-CoV-2 vaccine, compared immune responses from solidorgan transplant recipients (median age, 36.5 years) versus healthy patients (median age, 37.5 years), and observed significantly higher seropositivity in healthy versus transplant patients after Sinovac vaccination (100% vs 67.5%; P = .001). However, we observed no significant seropositive differences for Sinovac versus BioNTech second doses in transplant recipients. Median SARS-CoV-2 immunoglobulin G level after second dose was significantly higher in BioNTech (1388.6 AU/mL) versus Sinovac patients (136.6 AU/mL) (P = .012). The seropositivity difference between the 2 vaccines was significant in participants 24 to 44 years old (P = .040). The rate of at least 1 side effect was 82.4% (n = 14) for BioNTech vaccine and 32.3% (n = 10) for Sinovac vaccine, and the difference was statistically significant. The most common side effect was arm pain (significantly higher in BioNTech group). Conclusions: Solid-organ transplant recipients demonstrated inadequate vaccine responses (higher risk of complications and mortality) versus healthy patients. Furthermore, immune responses may differ between vaccines. Therefore, additional vaccine doses and strict control measures remain crucial.
Evaluation of Sepsis and Extensively Drug Resistant Infections in Deceased Critically Ill Patients
(2022) Yesiler, Fatma Irem; Yazar, Cagla; Ordu, Irem Ulutas; Sahinturk, Helin; Yalcin, Tugba Yanik; Zeyneloglu, Pinar; 0000-0003-0159-4771; 0000-0002-0612-8481; AAJ-1419-2021; AAJ-4212-2021
Objective: Sepsis due to the drug resistant infections is associated with the higher mortality rates in an intensive care unit (ICU). The aim of this study was to determine the demographic characteristics of the deceased critically ill patients, prevalence of the sepsis, and extensively drug resistant infectious-related (XDR) deaths within a year in the ICU. Materials and Methods: The data of patients who died in the ICU between January 1, 2019 and 2020 was retrospectively analyzed. Results: Out of 525 patients admitted to the ICU, 269 of them died. One hundred fifty-one of those deceased patients (56.1%) were in medical and 118 (43.9%) in the surgical ICU. Their mean age was 70.5 +/- 15 years and 126 (46.8%) of them were female. The mean Acute Physiology and Chronic Health Evaluation-II, Glasgow coma score, Sequential Organ Failure Assessment scores at ICU admission were 23.4 +/- 20.9, 9.8 +/- 4.4, and 8.2 +/- 3.6, respectively. A few reasons for the ICU admission were: respiratory failure (34.9%), neurologic dysfunction (19%), sepsis (17.8%), and cardiovascular failure (16%). Infection occurred in the 231 (85.9%) patients. Of the 109 (40.5%) deceased patients with the diagnosis of sepsis, 48 (40%) of them were admitted in the ICU with sepsis. The most common site of infection was the respiratory system (34.6%). Septic shock was seen in 170 patients (63.2%) and renal replacement therapy was needed in 61 (22.7%) of them. XDR developed in 34.6% of the deceased patients and was more frequent among those with an antibiotic usage before the ICU admission (p=0.02). The mean length of stay at hospital before the ICU admission and length of the ICU stay were 22 +/- 25.8 and 10.1 +/- 12.7 days, respectively. The number of the deceased medical patients were significantly higher than the surgical patients (p=0.018). Conclusion: The deceased critically ill medical patients were higher than the surgical patients. A total of 40% of the deceased critically ill patients were diagnosed with a sepsis, and one third of them had XDR infection. XDR infections were more frequent among the patients with an antibiotic usage before the ICU admission.
Herpes Zoster Infections in Solid-Organ Transplant Recipients
(2023) Sari, Nuran; Erol, Cigdem; Yalcin, Tugba Yanik; Azap, Ozlem Kurt; Arslan, Hande; Karakaya, Emre; Altinel, Cemile Tugba; Sezgin, Atilla; Incekas, Caner; Haberal, Mehmet; 0000-0002-4879-7974; 37885293; AAD-5466-2021
Objectives: Herpes zoster infections can be complicated and mortal in solid-organ transplant recipients. In our study, we investigated herpes zoster infections in solid-organ transplant recipients.Materials and Methods: Until June 2022, our center has performed 3342 kidney, 708 liver, and 148 heart transplants. Herpes zoster infections were investigated in 1050 adult solid-organ transplant recipients from January 1, 2011, to June 31, 2022. We studied 44 patients diagnosed with herpes zoster infections.Results: Of the 44 patients with herpes zoster, 32 had kidney, 7 had heart, and 5 had liver transplant procedures. Crude incidence rate was 5.2%.,with 9.7% being heart, 5.1% being kidney, and 3.9% being liver transplant recipients; 72.7% were male patients. The median age was 47.5 years, and 61% of patients were aged >45 years. Postherpetic neuralgia was significantly higher in patients older than 45 years (P = .006). The median duration to infection posttransplant was 16.5 months. The dermatomes of patients were 43.2% thoracic. Sacral dermatome involvement was significantly higher in heart transplant patients than in other transplant recipients (P = .015). We reviewed specific findings of the Tzanck test in 36.4% of the patients. There was concomitant infection in 15.9% of the patients, and 6.8% had pneumonia. Acute neuritis was more common in kidney transplant recipients (65.6%). The mean duration of acute neuritis/neuralgia was longest in liver transplant recipients (13.5 months; P = .047). Postherpetic neuralgia was detected as high as 24%.Conclusions: Early specific and supportive treatment is important for transplant recipients with herpes zoster infections. Appropriate antiviral prophylaxis regimens and vaccination strategies for varicella zoster (chickenpox) and herpes zoster infections should be implemented in the vaccination schedule of solid -organ transplant candidates to prevent herpes zoster infections and complications.
LAST TWO INFLUENZA SEASON: EVALUATION OF SOLID ORGAN TRANSPLANT RECIPIENTS
(2020) Yalcin, Tugba Yanik; Erol, Cigdem; Sari, Nuran; Arslan, Hande; Karakaya, Emre; Haberal, Mehmet A.
URINARY TRACT INFECTIONS IN RENAL TRANSPLANT RECIPIENTS IN THREE YEARS
(2020) Sari, Nuran; Erol, Cigdem; Yalcin, Tugba Yanik; Arslan, Hande; Haberal, Mehmet A.